HDFC Pharma and Healthcare Fund
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Growthvine rating: 4/5 — ranked #18 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹22.65 (as of 2026-11-13) |
|---|
| AUM | ₹3,501 Cr |
|---|
| Expense ratio | 1.64% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nikhil Mathur |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| Sharpe ratio | 1.33 |
|---|
| Standard deviation | 16.11% |
|---|
| Max drawdown | −15.07% |
|---|
| Alpha | 5.17 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 102.9% of NIFTY Pharma's upside and 74.1% of its downside.
Market cap allocation
| Large cap | 30.1% |
|---|
| Mid cap | 32.0% |
|---|
| Small cap | 37.9% |
|---|
Concentration
| Top 5 holdings | 33.8% |
|---|
| Top 10 holdings | 51.7% |
|---|
| Total holdings | 38 |
|---|
Top holdings
- Divis Laboratories Ltd. — 9.4%
- Sun Pharmaceutical Industries Ltd. — 7.7%
- Dr. Reddys Laboratories Ltd. — 6.7%
- Apollo Hospitals Enterprises Ltd. — 5.2%
- Alkem Laboratories Limited — 4.8%
- Cipla Ltd. — 4.1%
- ACUTAAS CHEMICALS LIMITED — 3.7%
- Max Healthcare Institute Limited — 3.4%
- Aster DM Healthcare Limited — 3.4%
- Lupin Ltd — 3.3%
Top sectors
- Pharma & Biotech — 70.9%
- Healthcare — 27.0%
- Cash — 1.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 31.4% | Q1 (Top) | #2 of 76 |
| 2025 | 1.2% | Q2 | #29 of 69 |
| 2024 | 50.3% | Q1 (Top) | #1 of 58 |